Scarica l'app Stockscreener
4.00
2.91%
-0.12
Rezolute Inc Borsa (RZLT) Ultime notizie
Rezolute Gets US FDA Breakthrough Therapy Designation for Hypoglycemia Treatment - marketscreener.com
Rezolute (RZLT) Gains FDA Breakthrough Status for Hypoglycemia Treatment | RZLT Stock News - GuruFocus
FDA grants breakthrough status to Rezolute’s hypoglycemia therapy - Investing.com
FDA grants breakthrough status to Rezolute’s hypoglycemia therapy By Investing.com - Investing.com India
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times
FDA Breakthrough: New Drug Shows Promise Against Life-Threatening Tumor-Induced Hypoglycemia - Stock Titan
Renaissance Technologies LLC Reduces Stake in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Inc (RZLT) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Rezolute to Participate in Upcoming Investor Conferences - The Manila Times
Rezolute: RZ402 Could Be A Surprise Candidate In The Making (NASDAQ:RZLT) - Seeking Alpha
Wedbush gives an Outperform recommendation for Rezolute Inc (RZLT) - knoxdaily.com
Market Recap: Rezolute Inc (RZLT)’s Positive Momentum, Closing at 3.86 - DWinneX
Rezolute’s $90 Million Common Stock Offering - Global Legal Chronicle
Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright - Defense World
Geode Capital Management LLC Has $2.54 Million Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Closes $96.9 Million Underwritten Offering - TipRanks
Rezolute (RZLT) SunRIZE Trial Progresses Without Changes | RZLT Stock News - GuruFocus
Analysts Set Rezolute, Inc. (NASDAQ:RZLT) PT at $26.43 - Defense World
Rezolute, Inc. Announces Closing of Underwritten Offering | RZLT Stock News - GuruFocus
Rezolute Closes Underwritten Share Offering - marketscreener.com
Rezolute, Inc. Announces Closing of Underwritten Offering - The Manila Times
Rezolute, Inc. Closes $96.9 Million Offering of Common Stock and Pre-Funded Warrants - Nasdaq
Rezolute Secures Massive $97M Funding: Blackstone, Federated Hermes Back Oversubscribed Round - Stock Titan
Mintz Advises on $90 Million Underwritten Offering by Rezolute - Mintz
Rezolute gets positive recommendation from IDMC to continue Ersodetug study - MSN
Rezolute Inc [RZLT] Records 50-Day SMA of $3.52 - knoxdaily.com
Investor’s Delight: Rezolute Inc (RZLT) Closes Strong at 3.97, Up 27.65 - DWinneX
Rezolute’s insulin disorder trial gets nod to move forward with no need to add new patients - koreabiomed.com
Rezolute’s sunRIZE trial to proceed without changes By Investing.com - Investing.com South Africa
Rezolute targets $90 million fundraise after positive late-stage trial newsSan Francisco Business Times - The Business Journals
Rezolute sets $90 million stock and warrant offering By Investing.com - Investing.com South Africa
Rezolute Announces Pricing of Direct Stock Offering - TipRanks
Rezolute Prices $90 Mln Offering With Common Stock And Pre-Funded Warrants - Nasdaq
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December - Benzinga
Biotech Stock Surges After Encouraging Data Monitoring Committee Recommendation - The Globe and Mail
Rezolute announces DMC recommendation to continue Phase 3 sunRIZE study - TipRanks
Rezolute Raises $90 Mln Through Stock And Warrant Offering To Support HI Drug Pipeline - Nasdaq
Rezolute stock rises after pricing $90M securities offering - MSN
Rezolute’s Promising Clinical Developments and Positive Outlook: A Buy Recommendation by Yun Zhong - TipRanks
Rezolute (RZLT) Launches $90 Million Stock Offering Priced at $3 - GuruFocus
Rezolute Receives Positive DMC Recommendation for Phase 3 Study - TipRanks
Rezolute Gets Independent DMC's Positive Recommendation to Continue Ersodetug Study -- Shares Surge Pre-Bell - marketscreener.com
Rezolute sets $90 million stock and warrant offering - Investing.com Australia
Rezolute’s sunRIZE trial to proceed without changes - Investing.com
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants | RZLT Stock News - GuruFocus
Rezolute (RZLT) Advances Phase 3 sunRIZE Trial Following Positiv - GuruFocus
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ('HI”) - The Manila Times
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants - The Manila Times
Rezolute, Inc. Announces Pricing of Underwritten Offering for 20.8 Million Shares at $3.25 Per Share - Nasdaq
Rezolute Announces Pricing Of Offering Of $90 Million Of Common Stock And Pre-Funded Warrants - marketscreener.com
Rezolute's Massive $90M Stock Offering Draws Blackstone, Federated Hermes Investment Giants - Stock Titan
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 ... - Enidnews.com
Major Clinical Milestone: Independent Committee Endorses Rare Disease Drug Trial for Congenital HI - Stock Titan
Rezolute Inc: Weathering Stock Market Storms with 190.08M Market Cap - investchronicle.com
Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Understanding RZLT stock ratios for better investment decisions - uspostnews.com
Rezolute, Inc. (NASDAQ:RZLT) Position Boosted by American Century Companies Inc. - Defense World
2.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):